Format

Send to

Choose Destination
Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e02008-16. doi: 10.1128/AAC.02008-16. Print 2017 Feb.

In Vitro Activities of Lefamulin and Other Antimicrobial Agents against Macrolide-Susceptible and Macrolide-Resistant Mycoplasma pneumoniae from the United States, Europe, and China.

Author information

1
Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA kwaites@uabmc.edu.
2
Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
3
Sexually Transmitted Bacterial Infections, Research and Development, Statens Serum Institut, Copenhagen, Denmark.
4
Institute of Antibiotics, Huashan Hospital, Fudan University, and China Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China.
5
Nabriva Therapeutics AG, Vienna, Austria.

Abstract

Lefamulin, an investigational pleuromutilin, was tested against a collection of 18 macrolide-susceptible and 42 macrolide-resistant Mycoplasma pneumoniae strains, and the results were compared with those of azithromycin, erythromycin, tetracycline, doxycycline, and moxifloxacin testing. Lefamulin was highly active against all strains tested, with all MICs at ≤0.008 μg/ml. The lefamulin MIC90 (0.002 μg/ml) for macrolide-resistant strains was the lowest among all drugs tested. Minimum bactericidal concentrations were within 2 dilutions of the MIC values, indicating a bactericidal effect.

KEYWORDS:

Mycoplasma pneumoniae; lefamulin; pleuromutilin; pneumonia; susceptibility testing

PMID:
27855075
PMCID:
PMC5278710
DOI:
10.1128/AAC.02008-16
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center